HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rafael Rosell Selected Research

dacomitinib

2/2021Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
9/2019Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer.
8/2019Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer.
1/2018Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
11/2017Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
9/2012Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Rafael Rosell Research Topics

Disease

257Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2022 - 02/2001
179Neoplasms (Cancer)
11/2022 - 02/2001
115Lung Neoplasms (Lung Cancer)
03/2022 - 02/2002
38Adenocarcinoma of Lung
03/2022 - 06/2005
18Disease Progression
01/2022 - 10/2003
13Melanoma (Melanoma, Malignant)
01/2018 - 02/2006
13Breast Neoplasms (Breast Cancer)
12/2016 - 10/2004
11Adenocarcinoma
10/2019 - 03/2004
10Neoplasm Metastasis (Metastasis)
02/2021 - 11/2011
9Squamous Cell Carcinoma (Epidermoid Carcinoma)
10/2022 - 06/2010
7Brain Neoplasms (Brain Tumor)
12/2021 - 07/2013
7Circulating Neoplastic Cells
01/2019 - 04/2013
6Diarrhea
02/2021 - 03/2004
6Ovarian Neoplasms (Ovarian Cancer)
12/2016 - 07/2002
6Neutropenia
03/2012 - 12/2002
5Carcinogenesis
01/2022 - 12/2005
5Colorectal Neoplasms (Colorectal Cancer)
12/2017 - 04/2002
5Stomach Neoplasms (Stomach Cancer)
03/2017 - 10/2011
5Small Cell Lung Carcinoma (Small Cell Lung Cancer)
09/2012 - 02/2001
5Febrile Neutropenia
11/2008 - 12/2002
4Glioblastoma (Glioblastoma Multiforme)
10/2021 - 04/2003
4Sarcoma (Soft Tissue Sarcoma)
01/2019 - 06/2012
4Hypersensitivity (Allergy)
03/2017 - 10/2004
3Leukemia
01/2019 - 02/2001
3Xeroderma Pigmentosum (Kaposi's Disease)
01/2017 - 08/2003
3Exanthema (Rash)
02/2016 - 03/2012
2Carcinoma (Carcinomatosis)
10/2022 - 03/2017
2Dermatitis
02/2021 - 11/2017

Drug/Important Bio-Agent (IBA)

79ErbB Receptors (EGF Receptor)IBA
01/2022 - 03/2004
61Tyrosine Kinase InhibitorsIBA
01/2022 - 03/2004
43Cisplatin (Platino)FDA LinkGeneric
06/2020 - 02/2002
39Messenger RNA (mRNA)IBA
01/2022 - 07/2002
38Biomarkers (Surrogate Marker)IBA
01/2022 - 04/2002
35Erlotinib Hydrochloride (CP 358,774)FDA Link
10/2019 - 03/2006
32PlatinumIBA
10/2022 - 06/2004
29DNA (Deoxyribonucleic Acid)IBA
01/2021 - 01/2003
21GemcitabineFDA Link
04/2020 - 02/2002
21Docetaxel (Taxotere)FDA Link
01/2020 - 12/2002
20Immune Checkpoint InhibitorsIBA
12/2021 - 09/2015
20Gefitinib (Iressa)FDA Link
02/2021 - 03/2004
19Proteins (Proteins, Gene)FDA Link
01/2021 - 03/2006
18Cell-Free Nucleic AcidsIBA
01/2021 - 12/2005
17Pharmaceutical PreparationsIBA
01/2020 - 12/2002
15Anaplastic Lymphoma KinaseIBA
03/2021 - 04/2014
14osimertinibIBA
03/2022 - 01/2017
14CrizotinibIBA
01/2021 - 12/2011
12Phosphotransferases (Kinase)IBA
01/2022 - 02/2010
12Pemetrexed (MTA)FDA Link
01/2016 - 04/2002
11RNA (Ribonucleic Acid)IBA
01/2022 - 01/2009
11Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
10/2021 - 06/2005
9AntibodiesIBA
01/2021 - 12/2010
9Biological ProductsIBA
06/2020 - 03/2004
9LigandsIBA
01/2020 - 11/2011
9Carboplatin (JM8)FDA LinkGeneric
01/2016 - 08/2003
8VaccinesIBA
01/2021 - 02/2006
8Vinorelbine (Navelbine)FDA LinkGeneric
01/2019 - 12/2002
7Bevacizumab (Avastin)FDA Link
09/2021 - 06/2010
7ParaffinIBA
01/2017 - 07/2002
6Circulating Tumor DNAIBA
11/2021 - 01/2016
6dacomitinibIBA
02/2021 - 09/2012
6pembrolizumabIBA
10/2020 - 01/2015
6Fluorouracil (Carac)FDA LinkGeneric
04/2020 - 04/2002
6Ribonucleotide Reductases (Ribonucleotide Reductase)IBA
01/2017 - 12/2002
6Paclitaxel (Taxol)FDA LinkGeneric
07/2011 - 08/2003
5Tumor Biomarkers (Tumor Markers)IBA
01/2022 - 08/2002
5Epidermal Growth Factor (EGF)IBA
01/2021 - 11/2002
5Monoclonal AntibodiesIBA
01/2020 - 01/2015
5Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
01/2020 - 02/2001
5Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
08/2016 - 06/2013
4NivolumabIBA
10/2022 - 01/2015
4AfatinibIBA
03/2022 - 01/2014
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2021 - 02/2008
4alectinibIBA
01/2021 - 06/2015
4B7-H1 AntigenIBA
10/2020 - 09/2015
4Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
09/2019 - 06/2013
4Irinotecan (Camptosar)FDA LinkGeneric
11/2017 - 12/2002
3Metformin (Glucophage)FDA LinkGeneric
03/2022 - 11/2019
3Phosphoric Monoester Hydrolases (Phosphatases)IBA
11/2020 - 01/2019
3dabrafenibIBA
09/2019 - 06/2013
3Platinum Compounds (Compounds, Platinum)IBA
03/2017 - 05/2007
3Cancer VaccinesIBA
12/2015 - 02/2006
3Indicators and Reagents (Reagents)IBA
05/2015 - 10/2004
3Cetuximab (Erbitux)FDA Link
02/2014 - 12/2002
3RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
11/2013 - 02/2001
3EnzymesIBA
06/2013 - 07/2003
3Codon (Codons)IBA
06/2011 - 01/2003
3Epirubicin (Ellence)FDA LinkGeneric
03/2010 - 11/2004
2IpilimumabIBA
10/2022 - 08/2016
2atezolizumabIBA
10/2022 - 01/2020
2Oncogene Proteins (Oncogene Protein)IBA
01/2022 - 01/2019

Therapy/Procedure

115Drug Therapy (Chemotherapy)
10/2022 - 02/2001
105Therapeutics
10/2022 - 02/2001
38Immunotherapy
01/2022 - 01/2015
14Adjuvant Chemotherapy
01/2019 - 02/2001
9Radiotherapy
12/2021 - 01/2006
6Neoadjuvant Therapy
12/2018 - 04/2002
3Precision Medicine
10/2020 - 10/2013
3Aftercare (After-Treatment)
01/2020 - 07/2002
3Chemoradiotherapy
01/2019 - 01/2015
3Induction Chemotherapy
01/2017 - 10/2007